| NASDAQ (usa) |
 |
6715.56 | -12.11 | -0.18% |
| FTSE 100 (london) |
|
7487.96 | -5.12 | -0.07% |
| DAX (german) |
 |
13465.51 | 235.94 | 1.78% |
| NIKKEI 225 (japan) |
|
22420.08 | 408.47 | 1.86% |
| Hang - Seng (hong kong) |
|
28594.06 | 348.52 | 1.23% |
| NIFTY - 50 (india) | ||||
| Straits Times (singapore) |
|
3391.61 | 17.53 | 0.52% |
| KOSPI (korea) |
|
2556.47 | 33.04 | 1.31% |
| All Ordinaries (australia) |
|
6005.30 | 28.90 | 0.48% |
| BOVESPA (brazil) |
|
74092.76 | -215.73 | -0.29% |
eFFECTOR Therapeutics Inc (NASDAQ: EFTRW)
EFTRW Technical Analysis
5
| As on 1st Jul 2022 EFTRW Share Price closed @ 0.25 and we RECOMMEND Strong Sell for LONG-TERM with Stoploss of 0.70 & Strong Sell for SHORT-TERM with Stoploss of 1.58 we also expect STOCK to react on Following IMPORTANT LEVELS. |
EFTRW Share Price
| Open | 0.23 | Change | Price | % |
| High | 0.25 | 1 Day | 0.00 | 0.00 |
| Low | 0.20 | 1 Week | -0.03 | -10.71 |
| Close | 0.25 | 1 Month | -0.06 | -19.35 |
| Volume | 42 | 1 Year | -0.35 | -58.33 |
| 52 Week High 2.25 | 52 Week Low 0.12 | ||||
NASDAQ USA Most Active Stocks
| ENDP | 0.57 | 21.28% |
| ALNA | 0.21 | 10.53% |
| XELA | 0.11 | 0.00% |
| AMD | 73.67 | -3.66% |
| CLVS | 2.85 | 58.33% |
| AKBA | 0.39 | 11.43% |
| AMZN | 109.56 | 3.15% |
| AAPL | 138.93 | 1.62% |
| NVDA | 145.23 | -4.20% |
| AGRX | 0.64 | -45.30% |
NASDAQ USA Top Gainers Stocks
NASDAQ USA Top Losers Stocks
| EFTRW Daily Charts |
EFTRW Intraday Charts |
Whats New @ Bazaartrend |
EFTRW Free Analysis |
|
|
EFTRW Important Levels Intraday
| RESISTANCE | 0.35 |
| RESISTANCE | 0.32 |
| RESISTANCE | 0.30 |
| RESISTANCE | 0.28 |
| SUPPORT | 0.22 |
| SUPPORT | 0.20 |
| SUPPORT | 0.18 |
| SUPPORT | 0.15 |
EFTRW Target for Month July
| 4th UP TARGET | 3.43 |
| 3rd UP TARGET | 2.41 |
| 2nd UP TARGET | 1.78 |
| 1st UP TARGET | 1.15 |
| 1st DOWN TARGET | -0.65 |
| 2nd DOWN TARGET | -1.28 |
| 3rd DOWN TARGET | -1.91 |
| 4th DOWN TARGET | -2.93 |
EFTRW Weekly Target
| 4th UP TARGET | 4.24 |
| 3rd UP TARGET | 2.96 |
| 2nd UP TARGET | 2.17 |
| 1st UP TARGET | 1.38 |
| 1st DOWN TARGET | -0.88 |
| 2nd DOWN TARGET | -1.67 |
| 3rd DOWN TARGET | -2.46 |
| 4th DOWN TARGET | -3.74 |
EFTRW Target for Year 2022
| 4th UP TARGET | 5.01 |
| 3rd UP TARGET | 3.48 |
| 2nd UP TARGET | 2.54 |
| 1st UP TARGET | 1.6 |
| 1st DOWN TARGET | -1.1 |
| 2nd DOWN TARGET | -2.04 |
| 3rd DOWN TARGET | -2.98 |
| 4th DOWN TARGET | -4.51 |
eFFECTOR Therapeutics Inc ( NASDAQ USA Symbol : EFTRW )
Sector : Healthcare And Other Stocks in Same Sector
Sector : Healthcare And Other Stocks in Same Sector
EFTRW Business Profile
eFFECTOR Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of selective translation regulator inhibitors (STRIs) for the treatment of cancer. Its lead product candidate is Tomivosertib, an oral small-molecule inhibitor of MNK1/2 that is in phase 2b clinical trial for the treatment of patients with metastatic non-small cell lung cancer (NSCLC). The company is also developing Zotatifin, a small molecule designed to inhibit eukaryotic initiation factor 4A (eIF4E), which is in phase 1/2 clinical trial to treat patients with solid tumors. It has a collaboration agreement with Pfizer Inc. to develop inhibitors of eIF4E. The company was founded in 2012 and is headquartered in San Diego, California. Address:
© 2005-2021 BazaarTrend.com All rights reserved.
Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service
Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service